Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 22;224(10):1694-1698.
doi: 10.1093/infdis/jiab451.

Messenger RNA Vaccine Effectiveness Against Coronavirus Disease 2019 Among Symptomatic Outpatients Aged ≥16 Years in the United States, February-May 2021

Sara S Kim  1 , Jessie R Chung  1 , Edward A Belongia  2 , Huong Q McLean  2 , Jennifer P King  2 , Mary Patricia Nowalk  3 , Richard K Zimmerman  3 , Goundappa K Balasubramani  3 , Emily T Martin  4 , Arnold S Monto  4 , Lois E Lamerato  5 , Manjusha Gaglani  6   7 , Michael E Smith  6 , Kayan M Dunnigan  6 , Michael L Jackson  8 , Lisa A Jackson  8 , Mark W Tenforde  1 , Jennifer R Verani  1 , Miwako Kobayashi  1 , Stephanie J Schrag  1 , Manish M Patel  1 , Brendan Flannery  1
Affiliations

Messenger RNA Vaccine Effectiveness Against Coronavirus Disease 2019 Among Symptomatic Outpatients Aged ≥16 Years in the United States, February-May 2021

Sara S Kim et al. J Infect Dis. .

Abstract

Evaluations of vaccine effectiveness (VE) are important to monitor as coronavirus disease 2019 (COVID-19) vaccines are introduced in the general population. Research staff enrolled symptomatic participants seeking outpatient medical care for COVID-19-like illness or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing from a multisite network. VE was evaluated using the test-negative design. Among 236 SARS-CoV-2 nucleic acid amplification test-positive and 576 test-negative participants aged ≥16 years, the VE of messenger RNA vaccines against COVID-19 was 91% (95% confidence interval, 83%-95%) for full vaccination and 75% (55%-87%) for partial vaccination. Vaccination was associated with prevention of most COVID-19 cases among people seeking outpatient medical care.

Keywords: COVID-19; SARS-CoV-2; vaccine effectiveness.

PubMed Disclaimer

References

    1. Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight U.S. locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep 2021; 70:495–500. - PMC - PubMed
    1. Tenforde MW, Self WH, Naioti EA, et al. ; IVY Network Investigators; IVY Network. Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults—United States, March-July 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1156–62. - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, et al. ; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384:403–16. - PMC - PubMed
    1. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021; 384:1412–23. - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383:2603–15. - PMC - PubMed

Publication types